Acute Coronary Syndrome: Focus on Antiplatelet Therapy
Acute Coronary Syndrome: Focus on Antiplatelet Therapy
复制标题
DOI：
10.4037/ccn2016497
复制
发表时间：
2016-02-01
影响因子：
1.6
通讯作者：
Bobadilla, Rodel V.
中科院分区：
文献类型：
--
作者：
Bobadilla, Rodel V.
美国心脏协会/美国心脏病学会于2014年发布了2007年和2012年非ST段抬高急性冠状动脉综合征(NSTE-ACS)指南的重点更新。在2013年发布的另一份指南中描述了ST段抬高心肌梗死(STEMI)的处理。对指南的重点更新包含了双重抗血小板治疗的最新建议，包括使用最近获得食品和药物管理局批准的P2Y(12)抑制剂替卡雷尔。护理急性冠脉综合征患者的护士必须对此类患者的当前治疗指南有很好的了解，以帮助确保提供循证护理。这篇综述文章使用基于案例研究的方法来描述当根据患者的临床病史和表现特征为NSTE-ACS或STEMI患者选择适当的抗血小板治疗时，新指南如何影响临床决策。
The American Heart Association/American College of Cardiology in 2014 published a focused update of the 2007 and 2012 guidelines for non-ST-segment elevation acute coronary syndrome (NSTE-ACS). The management of ST-segment elevation myocardial infarction (STEMI) is described in a separate guideline published in 2013. The focused updates to the guidelines contain updated recommendations for dual antiplatelet therapy, including use of the P2Y(12) inhibitor ticagrelor, which was recently approved by the Food and Drug Administration. Nurses caring for patients with acute coronary syndrome must have a good understanding of the current treatment guidelines for such patients, to help ensure delivery of evidence-based care. This review article uses a case study-based approach to describe how the new guidelines affect clinical decision making when choosing appropriate antiplatelet therapy for patients with NSTE-ACS or STEMI, depending on the patient's clinical history and presenting characteristics.